Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Income Statement Analysis

See more : Cyber Apps World Inc. (CYAP) Income Statement Analysis – Financial Results

Complete financial analysis of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Biohaven Pharmaceutical Holding Company Ltd., a leading company in the Biotechnology industry within the Healthcare sector.

You may be interested

PVR INOX Limited (PVRINOX.BO) Income Statement Analysis – Financial Results
Lanbay Inc (LNBY) Income Statement Analysis – Financial Results
CollPlant Biotechnologies Ltd. (CLGN) Income Statement Analysis – Financial Results
Emergence Global Enterprises Inc. (EMRG.CN) Income Statement Analysis – Financial Results
Rojana Industrial Park Public Company Limited (ROJNA-R.BK) Income Statement Analysis – Financial Results

Biohaven Pharmaceutical Holding Company Ltd. (BHVN)

Industry: Biotechnology

Sector: Healthcare

Website: https://www.biohavenpharma.com

About Biohaven Pharmaceutical Holding Company Ltd.

Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications. The company also offers Troriluzole for spinocerebellar ataxia and obsessive compulsive disorders, as well as Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000/5500 for neuropsychiatric indications; and Verdiperstat, a product for multiple system atrophy and amyotrophic lateral sclerosis. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was incorporated in 2013 and is headquartered in New Haven, Connecticut.

Metric	2023	2022	2021	2020	2019	2017
Revenue	0.00	0.00	462.51M	0.00	0.00	0.00
Cost of Revenue	3.37M	1.39M	91.66M	72.00K	0.00	0.00
Gross Profit	-3.37M	-1.39M	370.85M	-72.00K	0.00	0.00
Gross Profit Ratio	0.00%	0.00%	80.18%	0.00%	0.00%	0.00%
Research & Development	373.28M	437.07M	181.49M	98.46M	344.67M	0.00
General & Administrative	56.90M	130.86M	37.41M	16.05M	134.45M	0.00
Selling & Marketing	5.87M	0.00	0.00	0.00	0.00	0.00
SG&A	62.77M	130.86M	37.41M	16.05M	134.45M	0.00
Other Expenses	0.00	-1.91M	1.21M	0.00	0.00	0.00
Operating Expenses	436.05M	567.93M	218.90M	114.51M	479.12M	0.00
Cost & Expenses	436.05M	567.93M	218.90M	114.51M	479.12M	0.00
Interest Income	17.73M	0.00	0.00	0.00	0.00	0.00
Interest Expense	0.00	0.00	0.00	0.00	-12.71M	0.00
Depreciation & Amortization	6.91M	1.39M	1.39M	72.00K	171.86K	52.52K
EBITDA	-429.14M	-462.80M	-217.51M	-114.43M	-479.12M	0.00
EBITDA Ratio	0.00%	0.00%	-47.03%	0.00%	0.00%	0.00%
Operating Income	-436.05M	-567.93M	-218.90M	-114.51M	-479.12M	0.00
Operating Income Ratio	0.00%	0.00%	-47.33%	0.00%	0.00%	0.00%
Total Other Income/Expenses	26.50M	-1.91M	6.47M	-4.16M	-49.26M	0.00
Income Before Tax	-409.55M	-569.84M	-212.43M	-118.67M	-528.39M	0.00
Income Before Tax Ratio	0.00%	0.00%	-45.93%	0.00%	0.00%	0.00%
Income Tax Expense	-1.38M	438.00K	1.37M	-134.30K	419.00K	0.00
Net Income	-408.17M	-570.28M	-213.80M	-118.67M	-528.81M	0.00
Net Income Ratio	0.00%	0.00%	-46.23%	0.00%	0.00%	0.00%
EPS	-5.73	-12.75	-5.97	-3.31	-10.91	0.00
EPS Diluted	-5.73	-12.75	-5.97	-3.31	-10.91	0.00
Weighted Avg Shares Out	71.20M	44.74M	35.82M	35.82M	48.49M	0.00
Weighted Avg Shares Out (Dil)	71.20M	44.74M	35.82M	35.82M	48.49M	0.00

Biohaven Initiates Pivotal Trial of Novel Investigational Drug for Treatment of Migraine

September 30, 2024prnewswire.com

Biohaven initiated a pivotal Phase 2 trial evaluating BHV-2100 in the acute treatment of migraine BHV-2100 is a potential first-in-class, potent, orally administered Transient Receptor Potential Melastatin-3 (TRPM3) antagonist— a novel, highly selective, and non-opioid investigational treatment being developed for...

BHVN Stock Up as Rare Neurological Disease Study Meets Primary Goal

September 24, 2024zacks.com

The pivotal BHV4157-206-RWE study evaluating Biohaven's pipeline candidate, troriluzole, for treating spinocerebellar ataxia meets its primary endpoint.

Biohaven Stock Soars on Drug Trial Results: Time to Jump In?

September 24, 2024marketbeat.com

Biohaven Ltd. NYSE: BHVN has taken center stage in the biopharmaceutical sector after releasing positive results from its Phase 3 clinical trial for troriluzole, a drug being developed to treat spinocerebellar ataxia (SCA).

Overlooked Stock: BHVN

September 23, 2024youtube.com

Biohaven (BHVN) shares surged after the company's troriluzole drug showed significant slowed progression of spinocerebellar ataxia, a rare neurological disease. George Tsilis shares how the promising results can mark the beginning of a long road to success for Biohaven.

Biohaven: Positive SCA Treatment Data Leads To Q4 2024 NDA Submission Catalyst

September 23, 2024seekingalpha.com

Biohaven Ltd. reported positive results from a pivotal study using troriluzole for the treatment of patients with spinocerebellar ataxia; the Drug achieved 50% to 70% of slowing of disease progression over 3 years. With positive data on hand from the...